FDA Determines Regulatory Review Period for IXIARO Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for IXIARO, a human biological product, in accordance with federal regulations, following a patent extension application submitted to the US Department of Commerce.